Recurrent Glioblastoma Treated with Recombinant Poliovirus
2018 · New England Journal of Medicine · 768 citations
https://doi.org/10.1056/nejmoa1716435
A
Annick Desjardins
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
439
Papers
15.7K
Citations
60
h-index
142
i10-index
Annick Desjardins is an academic researcher. The author has contributed to research in topics: Glioma Diagnosis and Treatment & Brain Metastases and Treatment & Cancer Research and Treatments. The author has an h-index of 60, co-authored 374 publications.
ORCID: 0000-0003-3869-8283Papers by this author
worksPhase I Trial of Temozolomide Plus <i>O</i><sup>6</sup>-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
2005 · Journal of Clinical Oncology · 291 citations
https://doi.org/10.1200/jco.2005.06.502
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
2020 · Investigational New Drugs · 125 citations
https://doi.org/10.1007/s10637-020-00910-9
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
2021 · Nature Communications · 119 citations
https://doi.org/10.1038/s41467-020-20469-6
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
2012 · British Journal of Cancer · 91 citations
https://doi.org/10.1038/bjc.2012.415
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
2020 · Investigational New Drugs · 57 citations
https://doi.org/10.1007/s10637-020-00950-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat